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Abstract
Aim. To analyze the changes of advanced glycation end products (AGE) and galectin-3, their relationship in patients with 
chronic heart failure (CHF) and atrial fibrillation (AF), depending on the renal functional and age.
Material and methods. 30 patients with CHF II-III FC according to the classification of the New York Heart Association 
(NYHA) with preserved systolic function were examined (EF>45 %, mean 58.73 [45.38, 88.00] %), mean age 66.86 [46.00, 85.00] 
years who were on treatment in the Regional Hospital after 
I. I. Mechnikov. Men accounted for 60 % (18 people), women – 40 % (12 people). All patients were with AF: 17 (56.7 %) – 
with a permanent form, 13 (43.3 %) – with persistent. The serum creatinine level was determined and the GFR was calculated by 
CKD-EPI. The level of galectin-3 in the blood was determined by immunofermentive analis using the “Human Galectin-3 Platinum 
ELISA” kit (GmbH, Austria) on the Stat Fax 2100 (USA) immunofermentive plate analyzer. The fluorescent AGEs in plasma were 
analysed by quantitative autofluorescence (fluorimeter Hoefer DQ 2000, USA) with fixed spectrum of excitation at 460 nm with 
20 % quinine solution as a standard with results expressed with conversion to glycated albumin.
Results. AGE (mean 1.579 [0.884, 2.796]) and galectin-3 (mean 8.542 [2.72, 17.73]) levels increased in 83.3 % (25 patients) 
and 23.3 % (7 patients) respectively. The level of galectin-3 increased with age (by 33.18 %, p<0.05), while the level of AGE did not 
have significant changes. Levels of AGE and galectin-3 increased with a decrease in GFR (by 18.9 %, p<0.05 and 18.44 %, p<0.05, 
respectively). The level of AGE and serum creatinine correlated to GFR (r=0.25, p<0.05 and r=–0.22, p<0.05, respectively), while 
the level of galectin-3 correlated to GFR (r=–0.16, p<0.05). Intake of irbesartan reduced the level of galectin-3 (by 21.66 %) and AGE 
(by 4.9 %). The level of serum creatinine was decreased (by 4.89 %) and GFR was increased (by 6.3 %) compared with the intake of 
ACE inhibitors (by 2.9 % and 1.02 %, respectively).
Discussion. The results showed changes in AGE with a decrease in GFR in patients with CHF and AF, which makes it pos-
sible to consider AGE, as a marker of cardiorenal syndrome and makes it promising to further study it. Galectin-3 showed itself not 
only as a diagnostic marker, but also as a dynamic (positive effect of using irbesartan). Irbesartan had comparable clinical efficacy 
with ACE inhibitors in patients with CHF and AF. 
Conclusions. Among patients with CHF and AF, the level of AGE was increased 83.3 % of patients, galectin-3 – in 23.3 %. 
Depending on the age, priority was given to galectin-3 (an increase of 33.18 %, p<0.05). The levels of AGE and galectin-3 depends 
of GFR and were increased (by 18.9 % and 18.44 %, p<0.05 respectively). The use of irbesartan showed a more significant positive 
effect on the level of galectin-3 and AGE with GFR in the range <60≥30 ml/min/1.73 m2.
Keywords: glycation end products, galectin-3, glomerular filtration rate, chronic heart failure, atrial fibrillation. 
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1. Introduction
Chronic cardiovascular diseases (CVD) and chro kidney diseases (KD) are closely interre-
lated, and they share common risk factors. In the context of CVD and KD, interest in post-trans-
lational modifications (PTMs) of proteins has significantly increased. The analysis of PTMs can 
be useful in identifying mechanisms that play a role in the genesis and/or progression of CVD and 
KD, since proteins are constantly exposed to various plasma and tissue components under different 
pathophysiological conditions [1].
Glycation is the main cause of spontaneous disruption of the structure of intracellular and 
extracellular proteins of different physiological systems. In 0.1–0.2 % of cases, glycation passes 
through the residues of lysine and arginine [2]. In some areas where the metabolism of proteins is 
limited (for example, in the lens of the eye), the degree of glycation may increase in 10 times [2]. 
There are many products of the addition of glucose to proteins of tissues and body fluids in vivo. 
The earliest product of the addition of glucose to the protein is Ne-fructosyl-lysine (PL), with the 
slow degradation of which various advanced glycation end products (AGE) are formed. Dicarbonyl 
compounds of endogenous origin, as well as glyoxal, methylglyoxal and 3-deoxyglucosone have 
an expressed ability to glycate proteins. They are formed by the degradation of glycated proteins, 
intermediate metabolites of glycolysis and lipid peroxidation. Dicarbonyl compounds directly react 
with proteins to form AGE [2]. In the largest amount, hydroimidazolones are formed as the final 
glycation products, which are derivatives of arginine residues modified by glyoxal, methylglyox-
al and 3-deoxyglucosone (3-DG), -Nδ- (5-hydro-4-imidazolon-2-yl) ornithine G-H1), Nδ-(5-hy-
dro-5-methyl-4-imidazolon-2-yl)ornithine (MG-H1) and Nδ-(5-hydro-5-(2,3,4-trihydroxybutyl) – 
4-imidazolon-2-yl)ornithine and related structural isomers (3DG-H). Other widely studied AGEs 
are Nδ-carboxymethyl-lysine (CML) and Nδ-carboxyethyl-lysine (CEL), as well as derivatives of 
cross-linking proteins – pentosidine and glucosezane [2]. 
Initially, glycation was considered a reaction of post-translational modification of proteins, 
primarily extracellular ones. It was assumed, that AGE slowly accumulates in the body throughout 
life, and the concentrations of AGE reflect the process of accumulation of attachment products. 
However, this is only true for chemically stable AGEs formed from long-lived proteins, while in 
physiological conditions PL and some other AGE (in particular, hydroimidazolones) have a rela-
tively short half-life (2–6 weeks) and can be formed from intracellular and short-lived extracellular 
proteins. In the degradation of proteins with glycation altered by structure, glycation products are 
released [2]. In vivo peptides of low molecular weight are found in small concentrations in the 
blood plasma and in urine, and they can also be glycated. The products of glycation of proteins 
and peptides are called “remnants of glycation products”, which corresponds to the nomenclature 
of amino acid residues in the composition of proteins. Free glycation products are glycated amino 
acids formed with complete proteolysis of glycated proteins and glycation of amino acids. They are 
excreted in the urine [2].
Glycation is the main cause of spontaneous breakdown of the structure of proteins in the 
body. AGE stimulates various pro-inflammatory and signaling metabolic pathways, and their ex-
cessive accumulation in the body is considered as one of the main factors in the pathogenesis of 
cardiovascular diseases [3]. The participation of AGE in the pathogenesis of vascular complications 
is confirmed by the following experimental data: 
1) accumulation of AGE residues at the sites of vascular injuries; 
2) against the background of a change in the structure of vascular cell proteins under the 
influence of AGE in vitro, cell dysfunction is observed; 
3) inhibitors of AGE formation suppress the development of vascular complications (accord-
ing to the data of the conducted experiments and clinical studies).
Atrial fibrillation (AF) is one of the most common arrhythmias, a prevalence that increases 
as the population age growth [4]. Molecular mechanisms involved in atrial remodeling are not fully 
understood, but it is known that the pro-fibrosis and proinflammatory mechanisms increase the risk 
of AF. One such mechanism that occurs with aging involves the non-enzymatic binding of proteins 
and lipids leading to the formation of AGE [4]. AGE can play a role in the pathophysiology of PL 
through their interaction with cellular receptors for AGE (RAGE), which causes inflammation 
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and fibrosis through successive activation of the nuclear factor kappa B and increased expression 
of cytokines and adhesion molecules. Recent studies have shown that the interaction of AGE and 
RAGE can contribute to the onset of inflammation and oxidative stress [4]. These processes may 
also participate in the pathogenesis of AF, but their role remains debatable.
Various proteins are considered as specific receptors for AGE-modified proteins. Among the 
receptors located on the cell surface, they include the receptor of phagocytes, the receptor of the ad-
vanced glycation end products (RAGE) and galectin-3. Other AGE-binding proteins are localized 
in the cytoplasm and, possibly, they are not receptors for AGE [2]. Galectin-3 is considered as an 
AGE receptor, as evidenced by the ability of high-glycated albumin to interact with recombinant 
galectin-3, as well as the specific capture of galectin-3 by macrophages of RAW mice by the same 
ligand [2]. In vitro galectin-3 provides protection for mesangial cells, prevents the attack of infil-
trating macrophages and cytotoxic effects of TGF-β, affects the interaction of proteoglycans during 
angiogenesis, and also has other intracellular and extracellular effects in vivo [2]. Indeed, galec-
tin-3 has a pro-inflammatory effect: in the case of nephropathy, galectin-3+ infiltrates macrophages 
in the distal tubules and glomerulus of the kidneys, and the nature of this infiltration correlates 
with the severity of nephropathy [2, 5]. Thus, proteins classified as AGE receptors are involved in 
the pathogenesis of vascular complications, but it is not completely known whether the functional 
activity of these receptors is enhanced under the influence of AGE-modified proteins in vivo [2]. 
It should be noted, that galectin-3 promotes the migration of macrophages, the proliferation of fi-
broblasts and the synthesis of collagen in cardiomyocytes [6, 7]. Increased expression of galectin-3 
causes remodeling of the left ventricle (LV), which is accompanied by cardiac dysfunction and a 
decrease in the contractile function of the heart [8, 9].
It is known that the accumulation of AGE is one of the causes of CHF, nephropathy. Studies 
have shown that angiotensin II receptor blockers (ARBs) can reduce the ability to bind AGE to hy-
pertensive patients. In this regard, our interest is the fact of studying glycation products in patients 
with CHF and AF, depending on the renal functional.
2. Aim of the research
To analyze the changes of advanced glycation end products (AGE) and galectin-3, their 
relationship in patients with chronic heart failure (CHF) and atrial fibrillation (AF), depending on 
the renal functional and age.
3. Materials and methods 
30 patients with CHF II-III FC according to the classification of the New York Heart As-
sociation (NYHA) with preserved systolic function were examined (EF>45 %, mean 58.73 [45.38, 
88.00] %), mean age 66.86 [46.00, 85.00] years who were on treatment in the Regional Hospital a 
fter I. I. Mechnikov. The study was conducted from December 2016 to December 2017. The obser-
vation period was 3 months. Among patients were 60 % (18 people) men and 40 % (12 people) wom-
en. All patients were with AF: 17 (56.7 %) – with a permanent form, 13 (43.3 %) – with persistent.
Verification of the diagnosis of CHF and AF was conducted according to the recommenda-
tions of the European Society of Cardiology [10, 11].
Inclusion criteria were the presence of CHF with a preserved ejection fraction (EF>45 %) under 
conditions of stably selected drug therapy, AF, glomerular filtration rate (GFR) <90≥30 ml/min/1.73 m2 
and informed consent of the patient.
Exclusion criteria were patients with CHF IV FC and acute heart failure; acute coronary 
syndrome; myocardial infarction and stroke up to 6 months; significant valvular heart disease, 
GFR<30 ml/min/1.73 m2.
For clinical evaluation of renal function, serum creatinine was determined using colorimet-
ric methods and the GFR was calculated by CKD-EPI according to the recommendations of the 
American National Federation of the Kidneys [12]. 
All patients were assessed with galectin-3 blood levels by immunofermentive analis using 
the “Human Galectin-3 Platinum ELISA” kit (GmbH, Austria) on the Stat Fax 2100 (USA) immu-
noassay plate analyzer. The base level was taken as 0 ng/ml. 
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The fluorescent AGEs in plasma were analysed by quantitative autofluorescence (fluorime-
ter Hoefer DQ 2000, USA) with fixed spectrum of excitation at 460 nm with 20 % quinine solution 
as a standard with results expressed with conversion to glycated albumin.
15 patients (the main group) who prior to inclusion in the study did not received ARBs or had 
a poor tolerance of ACE inhibitors, irbesartan was used at a dose of 150 mg orally once a day, with an 
insufficient antihypertensive effect (BP>140/90 mm Hg) after 1 week the dose of the drug was increased 
to 300 mg per day. 15 patients (comparison group) continued to receive therapy with ACE inhibitors. 
For statistical analysis of data was used STATISTICA v.6.1 (Statsoft Inc., USA) license 
program. Categorical variables were expressed as frequencies and percentages. With regard to 
continuous variables, the assumption of normality was tested with the Kolmogorov-Smirnov test. 
The variables that follow a normal distribution were expressed as mean ± standard deviation. The 
remaining variables were expressed as median and interquartile range. [13].
4. Results
During the examination, arterial hypertension (AH) of stage II was registered in 19 (63.3 %), 
stage III – in 5 (16.6 %) patients; AH of I degree – in 3 (10 %), II – in 18 (60 %), III – in 3 (10 %) 
patients 5 (16.7 %) – had a history of myocardial infarction (more than 6 month) (Table 1).
Table 1
Characteristics of patients with CHF and AF (n=30)
Indicators Patients with CHF and AF
                            Blood pressure (BP), mm Hg 
systolic (Ме [25 %; 75 %]) 141,50 [100; 180]
diastolic (Ме [25 %; 75 %]) 87,53 [70; 112]
Heart rate, contr. per min. (Ме [25 %; 75 %]) 77,00 [65; 98]
EF, % (Ме [25 %; 75 %]) 58,73 [45.38; 88]
Body mass index (BMI), kg/m2 
(Ме [25 %; 75 %]) 29,77 [23.55; 40.9]
                              Arterial hypertension, n (%)
II stage 19 (63.3 %)
III stage 5 (16.6 %) 
I degree 3 (10 %)
IІ degree 18 (60 %)
IІІ degree 3 (10 %)
History of myocardial infarction, n (%) 5 (16.7 %)
Patients were used treatment according to recommendations [10, 11] (Table 2).
Table 2
Drug therapy of patients with CHF and AF
Indicators Main group  (n=15)
Comparison group  
(n=15)
β-blockers, % 11 (73.3 %) 12 (80 %)
Diuretics, % 9 (60 %) 6 (40 %)
Calcium antagonists, % 3 (20 %) 2 (13.3 %)
Aspirin, % 12 (80 %) 12 (80 %)
Statins, % 6 (40 %) 8 (53.3 %)
Among the examined, 83.3 % of patients (25 people) had an elevated level of AGE (mean – 
1.579 [0.884, 2.796]) (normal level – 0.9–1.1 mg/ml). The level of galectin-3 was increased in 
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7 patients (23.3 %) (normal level <12 ng/ml), mean – 8.542 [2.72; 17.73], which corresponds to 
normal values.
The obtained results showed that an increase in the FC of CHF was not accompanied by a 
significant change in the levels of galectin-3 and AGE, but a tendency toward an increase in the 
indices of galectin-3 was noted, which corresponds to the literature data (Table 3).
Table 3
The level of AGE and galectin-3, depending of the FC in patients with CHF and AF
CHF and AF (n=30)
FC ІІ FC ІІІ
Galectin-3 7.987  
[3.11; 16.16]
8.746  
[2.72; 17.73]
AGE 1.641  
[1.088; 2.796]
1.556  
[0.884; 2.570]
It is known that in the development and progression of CHF plays an important role such a 
factor as age. In connection with this, the study of markers that determine the features of the course 
of CHF in different age groups is of great importance (Table 4).
Table 4
The level of AGE and galectin-3, depending of the age in patients with CHF and AF
CHF and AF (n=30)
45–59 ages 60–74 ages 75–85 ages
Galectin-3 6.875 
[3.85; 12.8]
8.293 
[2.72; 16.16]
10.290* 
[3.87; 17.73]
AGE 1.657 
[1.314; 2.120]
1.581 
[0.884; 2.796]
1.516 
[1.064; 2.028]
Note: * – the reliability of differences compared with the group of 45–59 years, p<0.05
The analysis showed that the level of galectin-3 increases with age (by 33.18 %, p<0.05), 
while the AGE level has no significant changes.
It is believed that the active accumulation of AGE in the blood is due to their reduced renal 
clearance. To clarify the role of AGE and galectin-3 in the development and progression of renal 
dysfunction, patients were further analysed depending on the level of GFR (Table 5). It should be 
noted that 6 patients (20 %) had normal renal function.
Table 5
The level of AGE and galectin-3 depending of GFR in patients with CHF and AF
GFR <90≥60 ml/min./1,73m2 (n=12) GFR <60≥30 ml/min./1,73m2 (n=12) 
Galectin-3 7.670 
[2.72; 17.73]
9.405 
[4.1; 16.2]*
AGE 1.444 
[0.884; 1.878]
1,781 
[0.952; 2.796]*
Note: * – the reliability of the differences compared to the GFR group <90≥60 ml/min/1.73 m2, p<0.05
The results showed that with a decrease in GFR there was an increase in the level of both 
AGE (by 18.9 %, p<0.05) and galectin-3 (by 18.44 %, p<0.05). Correlation analysis revealed a close 
relationship between the level of AGE, serum creatinine and GFR (r=0.25, p<0.05 and r=–0.22, 
p<0.05, respectively), while the level of galectin-3 correlated only with GFR (r=–0.16, p<0.05).
After 3 months of treatment, the level of galectin-3 (by 21.66 %) and AGE (by 4.9 %) was 
decreased (Table 6).
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Table 6
Effect of therapy on the level of galectin-3 and AGE in patients with CHF and AF
Main group Comparison group 
Before the treatment After the treatment Before the treatment After the treatment
Galectin-3 10.161  
[4.1; 17.73]
7.960  
[3.9; 14.7]
8.271  
[3.85; 16.16]
5.850  
[2.94; 13.48]
AGE 1.641  
[0.884; 2.796]
1.559  
[0.886; 2.890]
1.516  
[1.078; 2.120]
1.537  
[1.050; 2.340]
Against the backdrop of treatment with irbesartan, a decrease in the level of serum creati-
nine (by 4.89 %) and an increase in GFR (by 6.3 %) compared with the use of ACE inhibitors (by 
2.9 % and 1.02 %, respectively) were detected.
The inclusion of irbesartan contributed to a significant decrease in the level of galectin-3 
among patients with GFR <60≥30 ml/min/1.73 m2 (p<0.05) compared with GFR<90≥60 ml/min/ 
1.73 m2 (Fig. 1).
Fig. 1. Dynamics of the level of galectin-3 in patients with CHF and AF who intake irbesartan: 
* – the reliability of differences compared with the baseline, p<0.05
Against the backdrop of treatment, there was a trend towards a decrease in the level of AGE 
among patients with GFR <60≥30 ml/min/1.73 m2, while there were no significant changes in pa-
tients with CHF and AF with GFR <90≥60 ml/min/1,73 m2 (Fig. 2). 
Fig. 2. Dynamics of AGE level in patients with CHF and AF who intake irbesartan
4. Discussion
Accumulation of AGEs can be explained by certain cardiovascular changes, such as vessel 
stiffness, diastolic dysfunction and endothelial dysfunction. From the reports of Semba et al., it 
follows that a high concentration of AGE may be a risk factor for cardiovascular disease, but addi-
tional evidence is needed to confirm this statement [14, 15].
AGEs can promote the development of chronic heart failure (CHF) in two ways. First, 
AGEs affect the physiological properties of proteins in the extracellular matrix, creating cross-
links. Secondly, AGEs causes multiple changes in blood vessels and myocardium through 
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interaction with AGEs receptors. AGEs can cause diastolic, systolic and vascular dysfunction 
through these pathways. Subsequently, these disorders can lead to the development and pro-
gression of CHF [16].
Strong evidence has been obtained in favour of the fact that the residues of AGE accumu-
late in the zones of vascular lesions, namely in the glomeruli of the kidneys [2]. At the same time, 
AGE-modified proteins break down as a result of cellular proteolysis with the formation of free 
products of AGE and are excreted in the urine, and therefore, in the presence of uremia is noted 
their active accumulation. Several mechanisms underlying the renal dysfunction have been pro-
posed, for example, reduced renal perfusion, atherosclerosis and inflammation, endothelial dys-
function and neurohormonal activation [2]. Another possible mechanism may be an increase in 
AGEs. Accumulation of AGE in patients with renal dysfunction can occur in two ways. First, the 
increase in accumulation of AGE is due to a decrease in the clearance of the AGE decomposition 
products. After modification or degradation in the proximal glomeruli, AGEs are ultimately purged 
in urine [17]. Patients with renal dysfunction have a reduced clearance and, thus, occurs accumu-
lation of AGE. Secondly, oxidative stress is increased in patients with renal dysfunction, which 
also leads to an increase in AGE formation [17]. Thus, it can be assumed that AGEs are a possible 
mechanism underlying the renal dysfunction. However, while the concentration of AGE circulation 
and their potential toxicity have been extensively studied in renal failure, there is no information 
available in patients with CHF.
For more than 10 years, the problem of cardiovascular syndrome has been discussed in the 
world. A number of studies have shown the adverse effect of decreased renal function on the course 
and prognosis of CHF. To date, a steady trend towards the introduction in the world of unified pro-
tocols for the treatment of cardiovascular diseases has led to positive results: improving the quality 
of treatment of patients and reducing mortality. However, the uncertainty of specific measures for 
the treatment of patients with CHF with preserved ejection fraction (EF>45 %) and lack of satis-
factory results induce to search for new directions of treatment and determine the possibilities of 
existing methods of drug therapy [18].
In the recommendations of the American College of Cardiology (ACC) and the American 
Heart Association (AHA) in 2017 for the treatment of patients with CHF, it is recommended to 
achieve low blood pressure (130/80 mm Hg), which in turn raises the issue of whiter hard control 
of blood pressure. Particular attention in the recommendations is given to the use of angiotensin II 
receptor blockers [19]. There is an opinion that the ARBs have a nephroprotective effect. However, 
the CHARM study showed that the use of candesartan is ineffective in patients with impaired renal 
function. While another study IRMA 2, using irbesartan, it was noted that the drug contributed 
to a reduction in the occurrence of new cases of nephropathy and dialysis, and also reduced the 
progression of the disease [20]. 
5. Conclusions
1. Among the examined, the elevated level of AGE was 83.3 % of patients, galectin-3 – 23.3 %.
2. Galectin-3, unlike AGE, clearly varies depending on age (an increase of 33.18 %, 
p<0.05) and GFR (an increase of 18.44 %, p<0.05), that is has a greater impact range than AGE. 
However, AGE varies depending on GFR in patients with CRF (an increase of 18.9 %, p<0.05), 
which may indicate a real damage to the clearance model and the role of glycosylation in damage 
to kidney function.
3. Galectin-3 is a more dynamic factor, since a positive response was noted against the 
background of irbesartan, in contrast to AGE. Thus, it can be said that AGE is a marker that reflects 
the manifestations of cardiorenal syndrome, and galectin-3 is associated with age and dynamics of 
CHF itself.
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